CytoSeek: Delivering Transformative Cell Therapies
CytoSeek's mission is to deliver transformative cell therapies for cancer patients using our precision membrane engineering platform technology.
The company was founded by Professor Adam Perriman, Dr Tom Green, and Dr Ben Carter, having developed the technology at the University of Bristol.
CytoSeek is now engaged in proof of principle studies for multiple AMBPs in combination with immune cells, and is seeking to enhance cell therapies against solid tumours.
Who we are
Our core team combines expertise across synthetic biology, cell biology, and immunology, and is complemented by our relationships with key scientific advisers in the field of cell therapies.
CytoSeek Team and Board Members
Dr Ben Carter - CEO
Prof. Adam Perriman - Director, CSO
Keith MacDonald - Non-Executive Director (NED) and Chair
Dr Harry Destecroix - NED
Dr Cassie Doherty - NED
Supported By:
We are seeking partnerships to co-develop our technology with cell therapy developers. Please get in touch if you'd like further information.
